| Literature DB >> 35789833 |
Ali R Zomorrodi1,2,3, Colin Hemez4,5,6, Pol Arranz-Gibert4,5, Terrence Wu7, Farren J Isaacs4,5,6, Daniel Segrè3,8,9,10.
Abstract
Introducing heterologous pathways into host cells constitutes a promising strategy for synthesizing nonstandard amino acids (nsAAs) to enable the production of proteins with expanded chemistries. However, this strategy has proven challenging, as the expression of heterologous pathways can disrupt cellular homeostasis of the host cell. Here, we sought to optimize the heterologous production of the nsAA para-aminophenylalanine (pAF) in Escherichia coli. First, we incorporated a heterologous pAF biosynthesis pathway into a genome-scale model of E. coli metabolism and computationally identified metabolic interventions in the host's native metabolism to improve pAF production. Next, we explored different approaches of imposing these flux interventions experimentally and found that the upregulation of flux in the chorismate biosynthesis pathway through the elimination of feedback inhibition mechanisms could significantly raise pAF titers (∼20-fold) while maintaining a reasonable pAF production-growth rate trade-off. Overall, this study provides a promising strategy for the biosynthesis of nsAAs in engineered cells.Entities:
Keywords: Bioengineering; Bioinformatics; Metabolic engineering
Year: 2022 PMID: 35789833 PMCID: PMC9249619 DOI: 10.1016/j.isci.2022.104562
Source DB: PubMed Journal: iScience ISSN: 2589-0042
Figure 1Trade-off between pAF production and growth in nonengineered strains
(A) Overview of pAF production via heterologous expression of papBAC. Chorismate, the end-product of the shikimate pathway, is converted to p-aminophenylpyruvate by the PapBAC enzymes, which is then converted to pAF by host cell deaminases. Red lines indicate inhibitory interactions on the specified genes.
(B) aTc-inducible papBAC overexpression circuit used in this study. tetR: tetracycline repressor.
(C) pAF production as a function of aTc concentration in E. coli strain EcNR2 bearing the aTc-inducible papBAC overexpression cassette and grown in M9 minimal medium.
(D) pAF production and doubling time (relative to growth without aTc) for EcNR2 bearing the aTc-inducible papBAC overexpression cassette.
(E) GFP fluorescence and doubling time (relative to growth without aTc) for EcNR2 bearing GFP in the place of papBAC under an aTc-inducible expression cassette. All data in this figure are represented as mean +/− SD of three replicates (technical replicates for pAF titer; biological replicates for all other measurements).
Figure 2Computational design of a pAF-producing E. coli strain using a heterologous pathway
(A) The predicted pAF production levels as a function of the biomass production flux (i.e., growth).
(B) Identified metabolic interventions to enhance pAF production.
(C) The impact of predicted metabolic flux interventions (left panel) and the corresponding gene-level interventions inferred from gene-protein-reaction associations in the model (right panel) on the minimum pAF production in the metabolic network. A minimum of three reaction (or four gene) interventions are needed to achieve a non-zero minimum pAF production. Implementing interventions shown on the right in the bar graphs (i.e., any of the four reaction or gene knockouts) in addition to those shown on the left further improves the pAF production. The minimum pAF production level was obtained by minimizing the pAF production in the model while imposing the identified interventions.
Figure 3pAF production and growth rate trade-offs in engineered strains
(A) pAF production in strains with modulations in aTc-induced papBAC overexpression, vanillic acid-induced aroC overexpression, aromatic amino acid biosynthesis gene knockouts, and shikimate pathway feedback inhibitions. “GFP” condition denotes a strain bearing an aTc-inducible GFP overexpression cassette. All strains were grown in M9 minimal medium supplemented with phenylalanine, tryptophan, and tyrosine. Data are represented as mean +/− SD of two technical replicates.
(B) pAF production in strains with shikimate pathway feedback inhibition mutations (aroFG-FIM and ΔtyrR) and modulated papBAC and aroC overexpression. The strain in the top panel bears feedback inhibition mutations only, and the strain in the bottom panel bears knockouts in pheA, trpDE, and tyrA in addition to feedback inhibition mutations. Data are represented as the mean of three technical replicates.
(C) pAF production and doubling time (relative to the growth of EcNR2) for strains with different combinations of genomic interventions. Strains in which pAF production was not detected are not included. We observed an epistatic interaction between aroFG-FIM and ΔtyrR—both interventions in combination lead to substantial increases in pAF titer, whereas they lead to only minor increases in titer on their own. pAF data are represented as mean +/− SD of two technical replicates; doubling time data are represented as mean +/− SD of three biological replicates.
(D) Representative growth curves of EcNR2 and EcNR2.aroFG-FIM.ΔtyrR bearing aTc-inducible papBAC overexpression cassettes at 0 aTc (top panel) and 2 ng/μL aTc (bottom panel). Curves are the mean of three biological replicates.
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| Addgene | Addgene #26931 | |
| LB growth medium | AmericanBio | N/A |
| Solid chemicals: amino acids (phenylalanine, tryptophan, tyrosine), antibiotics (carbenicillin, spectinomycin), inducers (anhydrotetracycline, vanillic acid), trace minerals ( | SigmaAldrich | N/A |
| Colicin E1 for | This paper | N/A |
| This paper | CFH748-755 | |
| MAGE oligo for | This paper | oCFH007 |
| MAGE oligo for | This paper | oCFH008 |
| Primers for cloning pPAF-v5 and pGFP-RFP | This paper | rCFH404-415 |
| MAGE oligos for knockout of | This paper | oCFH026-29 |
| Primers for amplifying | This paper | rCFH334-337, 344-347, 511-512 |
| pPAF-v5 | This paper | CFH489 |
| pGFP-RFP | This paper | CFH496 |
| papBAC synthetic genes | GenScript | N/A |
| Python scripts for OptForce simulations | This paper | |
| Python v2.7.11 for Unix | Python Software Foundation | |
| MATLAB r2019a for doubling time calculations | MathWorks Inc | |
| Gurobi Optimizer v9.0.0 | Gurobi Optimization | |
| COBRApy Toolbox v0.9.1 | cobrapy - constraint-based metabolic modeling in Python | |
| SCC Shared Computing Cluster, SCC1, 2 fourteen-core 2.4 GHz Intel Xeon E5-2680v4, 256 Gb RAM, 2 nodes | Boston University Research Computing, Massachusetts Green High Performance Computing Center (MGHPCC), Holyoke, MA | |
| Yale West Campus Analytical Core | Yale University | |
| Experimental data and MATLAB analysis code for | This paper | |